lilly retatrutide trial A Study of (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) Lilly's triple agonist, retatrutide, delivered

The drug, called orforglipron and manufactured by Eli Lilly, is prescribed for type 2 diabetes and targets the same GLP-1 receptors as oral semaglutide

Two things we know at Noisy Guts from our pharmacists who assist GLP-1 users manage their gut symptoms day in, day out is that partially hydrolysed guar gum and protein are key

Interestingly, the SURPASS-2 trial found that patients on tirzepatide 5 mg experienced less nausea (17.4%) and vomiting (5.7%) compared to those on semaglutide 1 mg, who reported 19.2% nausea and 8.1% vomiting, despite tirzepatide leading to greater weight loss

On TikTok, Reddit, and some telehealth websites, microdosing glucagon-like peptide-1 (GLP-1) receptor agonist medications is pitched as a gentler, more flexible way to use drugs such as the GLP-1 agonist semaglutide (Ozempic, Wegovy), the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound), and oral nonpeptide GLP-1 receptor agonist orforglipron (Foundayo)

04 Swirl, don't shake Gently roll until fully dissolved